CNS Pharmaceuticals, Inc. CNSP
4.55 USD +0.16 (+3.64%)
At closeNov 3, 2026, 4:00 PM EST
4.55 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
4.00 Day range 4.70
1.90 52-week range 10.54
- YTD
- -13.33%
- 1 year
- -36.54%
- Market cap
- 6.65M
- EPS (ttm)
- -19.16
- Shares out
- 57.49M
- Forward P/E
- -0.28
- YTD return
- -13.33%
- 1-year return
- -36.54%
- Volume
- 13.87K
- Avg volume
- 9.14K
- Open
- 5.00
- Previous close
- 4.39
- Day's range
- 4.00 – 4.70
- 52-week range
- 1.90 – 10.54
- Beta
- 1.05
- Price target
- 0.50 (-89.0%)
No chart data for this range yet.
Key statistics
- Enterprise value
- 2.01M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.19M
- Total cash
- 1.49M
- Total debt
- 123.25K
- Return on equity
- 0.00%
- Short % of float
- 2.79%
- 50-day average
- 0.11872
- 200-day average
- 4.42
Analyst view
Price target (mean) 0.50
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
CNSP Revenue — quarterly 0
CNSP Net income — quarterly -2.59M
CNSP EPS — quarterly -0.38
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.25 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -6.72 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -20.50 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -47.50 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -54.00 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -52.00 | — | — |
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cnspharma.com
News
CNS Pharmaceuticals (NASDAQ:CNSP) Stock Jumps 1.5% – Here’s Why 
CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth 
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference 
CNS Pharmaceuticals Q2 EPS $(0.38) Misses $(0.24) Estimate 
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
Your note
Sign in to keep a note on CNSP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CLIMACO JOHN M | Chief Executive Officer | Purchase | Jan 31, 2024 | 215,676 |
| DOWNS CHRISTOPHER | Chief Financial Officer | Purchase | Jan 31, 2024 | 103,438 |
| EVANS CARL ANTHONY | Director | Purchase | Jan 31, 2024 | 33,458 |
| GUMULKA JERZY | Director | Purchase | Jan 31, 2024 | 43,006 |
| PRIEBE WALDEMAR PH.D. | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 27, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.35% | 203,180 | 22.15K | Sep 29, 2024 |
| UBS Group AG | 0.32% | 181,866 | 19.82K | Sep 29, 2024 |
| Virtu Financial LLC | 0.21% | 122,876 | 13.39K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 0.05% | 28,197 | 3.07K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.04% | 23,160 | 2.52K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 16,298 | 1.78K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.28% | 162,183 | 17.68K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 37,943 | 4.13K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 1,168 | 127 | Sep 29, 2024 |
| Blackstone Alternative Multi-Strategy Fund | 0.00% | 8 | 0 | Sep 29, 2024 |